Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.94 USD | +3.40% | +8.24% | -6.79% |
04-18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
04-17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.79% | 4.67B | |
+25.50% | 48.09B | |
+48.09% | 40.62B | |
-2.19% | 40.43B | |
-6.20% | 28.36B | |
+8.02% | 24.89B | |
-19.43% | 19.01B | |
+30.32% | 12.09B | |
+0.35% | 11.88B | |
+0.62% | 11.8B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Chardan Adjusts CRISPR Therapeutics' Price Target to $164 from $168, Keeps Buy Rating